Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Corvus Pharmaceuticals Inc CRVS

Healthcare Biotechnology
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in... see more

Recent & Breaking News (NDAQ:CRVS)

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

GlobeNewswire 13 days ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 19, 2024

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

GlobeNewswire March 13, 2024

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

GlobeNewswire February 12, 2024

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

GlobeNewswire February 8, 2024

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

GlobeNewswire February 6, 2024

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

GlobeNewswire January 23, 2024

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

GlobeNewswire December 9, 2023

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire November 7, 2023

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

GlobeNewswire November 2, 2023

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

GlobeNewswire November 1, 2023

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023

GlobeNewswire October 31, 2023

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

GlobeNewswire September 6, 2023

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 8, 2023

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

GlobeNewswire August 1, 2023

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

GlobeNewswire July 6, 2023

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

GlobeNewswire June 29, 2023

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

GlobeNewswire June 15, 2023

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

GlobeNewswire May 31, 2023

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

GlobeNewswire May 17, 2023